Non-alcoholic Fatty Liver Disease

This is a condition where fat builds up in the liver. It happens when someone drinks a lot of alcohol, but it can also occur in people who don't drink alcohol. It's a common liver problem.

Condition

What people with Non-alcoholic Fatty Liver Disease report

Every report comes from a Lived member, sent anonymously.

Have you tried Exercise Therapy for Non-alcoholic Fatty Liver Disease?

NameHow it went

About Non-alcoholic Fatty Liver Disease

What It Is

Non-alcoholic fatty liver disease (NAFLD) is a condition in which too much fat builds up in the liver for reasons other than heavy drinking. It is closely tied to how the body handles sugar and fat, so it usually appears alongside excess weight, type 2 diabetes, high cholesterol or high blood pressure. It is the most common long-term liver disease, estimated to affect a quarter to nearly a third of adults, and it often goes undiagnosed. For many people, the fat sits in the liver without causing much harm. In others, the fat comes with inflammation and injury to liver cells, a more active form called steatohepatitis. Over years, that injury can lead to scarring (fibrosis), and heavy scarring can become cirrhosis, which raises the risk of liver failure and liver cancer. The condition usually causes few or no symptoms, even at advanced stages. Some people notice tiredness or discomfort in the upper right side of the abdomen. Liver specialists have renamed the condition metabolic dysfunction-associated steatotic liver disease (MASLD), and its inflamed form metabolic dysfunction-associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH). The new names point to the metabolic problems behind the disease, and they increasingly appear on test reports and in clinic letters.

Causes & Risk Factors

Fatty liver disease is closely linked to insulin resistance, in which the body responds poorly to insulin, the hormone that keeps blood sugar in check. That is why it clusters with obesity (especially extra fat around the waist), prediabetes and type 2 diabetes, high triglycerides or abnormal cholesterol, and high blood pressure. The more of these a person has, the more likely the inflamed form becomes. Type 2 diabetes and abdominal obesity have the strongest influence on whether scarring progresses, and the risk of progression is also higher in men over 50 and in women after menopause. People at a healthy weight can develop it too. Genes play a part, which helps explain why it is more common in some families and ethnic groups; close relatives of someone with cirrhosis from this disease have a much higher risk of advanced scarring themselves. Diets heavy in added sugar, particularly the fructose in sweetened drinks, are associated with higher risk. Rapid weight loss and certain medicines, such as corticosteroids and some cancer drugs, can also contribute. Alcohol is not the cause by definition, but it still matters. Even moderate drinking is linked to more advanced scarring in people with fatty liver, and heavy drinking speeds up liver damage. When someone with these metabolic risk factors also drinks more than lightly, doctors may describe a combined condition (sometimes called MetALD) that carries a worse outlook than either alone.

How It's Diagnosed

Fatty liver is most often found by accident, on an ultrasound or scan done for another reason, or because routine blood tests show raised liver enzymes (ALT and AST, proteins that leak from stressed liver cells). Normal enzyme results do not rule it out: people with normal levels can still have inflammation and significant scarring. An evaluation has two goals. The first is confirming the cause. A clinician asks about alcohol and medicines and checks for other conditions, such as hepatitis C, that can also put fat in the liver. The second goal matters most for the future: estimating how much scarring is present, because the stage of fibrosis is the strongest predictor of whether liver problems will develop. The usual first step is a FIB-4 (fibrosis-4) score, calculated from age, two liver enzymes and the platelet count on ordinary blood tests. A score below 1.3 means advanced scarring is unlikely, and the score is typically rechecked every one to three years. A score above 2.67 makes advanced scarring more likely. Scores in between, or above 2.0 in people over 65, usually call for a second test. Most often that is transient elastography (FibroScan), a quick ultrasound-based scan that measures how stiff the liver is, since scar tissue makes the liver stiffer. Results are given in kilopascals (kPa): a reading below about 8 makes advanced scarring unlikely, while 12 or higher makes it more likely. A specialized blood test called the Enhanced Liver Fibrosis (ELF) test, or an MRI-based stiffness scan, is sometimes used instead. A liver biopsy, in which a needle removes a tiny sample of tissue, is now reserved for cases where the picture stays unclear or another diagnosis is suspected.

Treatment Options

Lifestyle change is the foundation of treatment at every stage, and it acts on the liver directly. Losing 3% to 5% of body weight reduces liver fat; losing 10% or more is generally needed to calm inflammation and improve scarring. No single eating pattern has proven best. Lower-carbohydrate, lower-fat and Mediterranean-style diets appear to work about equally well, so the right choice is one a person can sustain. Cutting back on sugar-sweetened drinks and refined carbohydrates is a common starting point. Regular exercise helps the liver and heart even when weight does not change; about 150 minutes of moderate activity a week is a typical goal. Keeping weight off is hard, and support from a dietitian or a structured program improves the odds. Avoiding heavy drinking is essential, and even moderate drinking is worth discussing with a clinician. For adults with the inflamed form and moderate to advanced scarring (fibrosis stages F2 to F3, on a scale from F0 for no scarring to F4 for cirrhosis) but not cirrhosis, two prescription medicines are FDA approved for use alongside diet and exercise. Resmetirom (Rezdiffra) is a daily tablet that activates a thyroid hormone receptor in the liver. Diarrhea and nausea are its most common side effects, it requires periodic liver blood tests, and it limits the dose of some statin cholesterol medicines. Semaglutide (Wegovy) is a weekly injection from the GLP-1 (glucagon-like peptide-1) class of medicines used for weight loss and diabetes; nausea, diarrhea and other stomach upset are common, especially early on. Both were approved because they improved inflammation and scarring on liver biopsies, and studies are still under way to confirm that they prevent cirrhosis and other long-term complications. Other options fit particular situations. For people who qualify for bariatric (weight-loss) surgery, it can resolve steatohepatitis and improve scarring. High-dose vitamin E and pioglitazone, a diabetes medicine, have reduced liver inflammation in trials and are sometimes used off-label for selected people. Each has trade-offs to discuss first: pioglitazone can cause weight gain, and long-term high-dose vitamin E has raised concerns about bleeding and prostate cancer. Treating diabetes, cholesterol and blood pressure is part of liver care too.

What to Expect

For most people, fatty liver disease is a long-term condition that changes slowly, if at all. Simple fatty liver usually does not progress to serious liver damage. In the inflamed form, scarring has been found to advance about one stage every seven years on average, though the pace varies widely between people. The direction is not fixed: weight loss can turn inflamed disease back into simple fatty liver, and weight regain can push it the other way. Because the same metabolic problems drive both, heart disease is a bigger threat than liver failure for most people with fatty liver disease, and it is the most common cause of death in this group. In daily life, that makes care look much like heart-health care: steady work on eating, activity and weight, and good control of blood sugar, cholesterol and blood pressure. Follow-up depends on the amount of scarring. With low-risk results, a primary care clinician typically repeats the FIB-4 score every one to three years. People with significant scarring usually see a liver specialist, and stiffness scans may be repeated to track change. People who have developed cirrhosis need an ultrasound to look for liver cancer about every six months, a check for enlarged veins in the esophagus, and closer monitoring of liver function.

When to Seek Help

Ask about a liver evaluation if a scan has shown fat in your liver or blood tests show raised liver enzymes, or if you have type 2 diabetes, obesity with other metabolic problems, or a close relative with cirrhosis. These groups are advised to be checked for scarring that causes no symptoms. Contact your care team promptly if you notice yellowing of the skin or the whites of the eyes, new swelling of the abdomen or legs, easy bruising or bleeding, dark urine, or new confusion or unusual drowsiness. These can be signs that the liver is struggling to work. Vomiting blood or passing black or bloody stools needs emergency care right away, because in people with cirrhosis this can mean bleeding from enlarged veins in the esophagus or stomach.

Questions to Ask Your Doctor

  1. 1.What do my FIB-4 score or stiffness scan results say about how much scarring I have?
  2. 2.How much weight loss would make a real difference for my liver, and what support can help me get there?
  3. 3.Am I a candidate for Rezdiffra, Wegovy or another treatment, and how would we know it is working?
  4. 4.How much alcohol, if any, is reasonable for me?
  5. 5.Which of my other conditions or medicines should we adjust to protect both my liver and my heart?

Last reviewed • Oct 2026

Educational content, not medical advice.